-
Medicare to limit coverage of controversial Alzheimer’s drug to clinical trial participants
–
Prior to CMS’s announcement, the possibility of Medicare covering Aduhelm had already driven increased Medicare Part B premiums.
-
Do cognitive biases underlie climate skepticism?
–
From the amount of attention devoted to the climate at the annual United Nations General Assembly this month to last week’s collaboration among […]
-
Congress upholds federal barriers to psychedelic drug research amidst broadening scientific acceptance
–
On Tuesday, members of the US House of representatives voted 140-285 against an amendment to a minibus appropriations bill that would have removed […]
-
Potential Alzheimer’s treatment approved by FDA
–
Biogen’s aducanamab could hit the market in a matter of days. While many in the Alzheimer’s community are encouraged by this news, the controversy surrounding the drug hasn’t gone anywhere.
-
Amazon’s “AmaZen” mindfulness strategy draws social media scrutiny
–
Tech giant Amazon’s new plan aimed at employee well-being elicited negative reactions across social media this week. The AmaZen initiative, announced in a […]
-
Recent court cases highlight police mistreatment of individuals with dementia
–
Earlier this month, a municipal court in Glendale, Arizona dismissed four charges of trespassing against city resident Sam Thomas after he was found […]
-
New federal guidelines facilitate treatment for opioid use disorder
–
Today the U.S. Department of Health and Human Services (HHS) released new guidelines waiving previous training requirements for doctors and other healthcare practitioners, […]
-
Extra support for early career researchers at stake in Congress
–
Last week, the Supporting Early Career Researchers Act (H.R. 144) was reported from the Committee on Science, Space, and Technology to the full […]